CN111094250A - 凋亡信号调节激酶抑制剂及其制备方法和应用 - Google Patents

凋亡信号调节激酶抑制剂及其制备方法和应用 Download PDF

Info

Publication number
CN111094250A
CN111094250A CN201880015032.5A CN201880015032A CN111094250A CN 111094250 A CN111094250 A CN 111094250A CN 201880015032 A CN201880015032 A CN 201880015032A CN 111094250 A CN111094250 A CN 111094250A
Authority
CN
China
Prior art keywords
group
alkyl
cycloalkyl
heteroaryl
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201880015032.5A
Other languages
English (en)
Other versions
CN111094250B (zh
Inventor
高鹏
谭松良
修文华
张福军
刘磊
包如迪
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Shanghai Hansoh Biomedical Co Ltd
Original Assignee
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Shanghai Hansoh Biomedical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hansoh Pharmaceutical Group Co Ltd, Shanghai Hansoh Biomedical Co Ltd filed Critical Jiangsu Hansoh Pharmaceutical Group Co Ltd
Priority to CN202211259633.5A priority Critical patent/CN115504986B/zh
Publication of CN111094250A publication Critical patent/CN111094250A/zh
Application granted granted Critical
Publication of CN111094250B publication Critical patent/CN111094250B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyridine Compounds (AREA)

Abstract

提供酰胺类衍生物抑制剂、其制备方法和应用。特别地，涉及通式(I)所示的化合物、其制备方法及含有该化合物的药物组合物，及其作为ASK1抑制剂在治疗神经退休性疾病、心血管疾病、炎症、自身免疫和代谢性疾病的用途，其中通式(I)中的各取代基与说明书中的定义相同。

Description

PCT国内申请，说明书已公开。

Claims (18)

  1. PCT国内申请，权利要求书已公开。
CN201880015032.5A 2017-03-03 2018-03-02 凋亡信号调节激酶抑制剂及其制备方法和应用 Active CN111094250B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202211259633.5A CN115504986B (zh) 2017-03-03 2018-03-02 凋亡信号调节激酶抑制剂及其制备方法和应用

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CN2017101237997 2017-03-03
CN201710123799 2017-03-03
CN201710713967 2017-08-18
CN2017107139678 2017-08-18
CN201810045023 2018-01-17
CN2018100450232 2018-01-17
PCT/CN2018/077873 WO2018157857A1 (zh) 2017-03-03 2018-03-02 凋亡信号调节激酶抑制剂及其制备方法和应用

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202211259633.5A Division CN115504986B (zh) 2017-03-03 2018-03-02 凋亡信号调节激酶抑制剂及其制备方法和应用

Publications (2)

Publication Number Publication Date
CN111094250A true CN111094250A (zh) 2020-05-01
CN111094250B CN111094250B (zh) 2022-11-04

Family

ID=63369764

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201880004515.5A Active CN109983007B (zh) 2017-03-03 2018-03-02 酰胺类衍生物抑制剂及其制备方法和应用
CN201880015032.5A Active CN111094250B (zh) 2017-03-03 2018-03-02 凋亡信号调节激酶抑制剂及其制备方法和应用
CN202211259633.5A Active CN115504986B (zh) 2017-03-03 2018-03-02 凋亡信号调节激酶抑制剂及其制备方法和应用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201880004515.5A Active CN109983007B (zh) 2017-03-03 2018-03-02 酰胺类衍生物抑制剂及其制备方法和应用

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202211259633.5A Active CN115504986B (zh) 2017-03-03 2018-03-02 凋亡信号调节激酶抑制剂及其制备方法和应用

Country Status (7)

Country Link
US (1) US11136324B2 (zh)
EP (1) EP3590931A4 (zh)
JP (1) JP7211959B2 (zh)
KR (1) KR20190126322A (zh)
CN (3) CN109983007B (zh)
TW (1) TW201833108A (zh)
WO (2) WO2018157856A1 (zh)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109956928A (zh) * 2017-12-14 2019-07-02 四川科伦博泰生物医药股份有限公司 吡啶类化合物、其制备方法及用途
CN110294746A (zh) * 2018-03-21 2019-10-01 山东轩竹医药科技有限公司 一种新的ask1抑制剂及其应用
CN110770233A (zh) * 2017-06-19 2020-02-07 广东东阳光药业有限公司 稠合双环类化合物及其在药物中的应用
CN111518080A (zh) * 2017-10-12 2020-08-11 深圳市塔吉瑞生物医药有限公司 一种1,2,4-三氮唑类化合物

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190221A1 (ar) 2017-04-05 2019-09-23 Seal Rock Therapeutics Inc مركبات مثبطات كيناز منظم لإشارات الاستماتة 1 (ask1) واستخداماتها
US10683279B2 (en) 2017-05-12 2020-06-16 Enanta Pharmaceuticals, Inc. Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
US10253018B2 (en) 2017-05-25 2019-04-09 Enanta Pharmaceuticals, Inc. Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
WO2018218044A2 (en) 2017-05-25 2018-11-29 Enanta Pharmaceuticals Inc Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
WO2018218051A1 (en) 2017-05-25 2018-11-29 Enanta Pharmaceuticals, Inc. Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
WO2019015559A1 (zh) * 2017-07-18 2019-01-24 南京圣和药业股份有限公司 作为ask抑制剂的杂环化合物及其应用
WO2019034096A1 (en) * 2017-08-17 2019-02-21 Sunshine Lake Pharma Co., Ltd. FUSED BICYCLIC COMPOUNDS AND THEIR USES IN MEDICINE
WO2019046186A1 (en) 2017-08-28 2019-03-07 Enanta Pharmaceuticals, Inc. INHIBITORS OF KINASE 1 REGULATING THE APOPTOTIC SIGNAL CONTAINING TETRAZOLES AND METHODS OF USE THEREOF
CN109456308B (zh) * 2017-09-06 2022-11-29 南京圣和药业股份有限公司 作为ask抑制剂的杂环化合物及其应用
EA202090871A1 (ru) 2017-10-06 2020-07-03 Форма Терапьютикс, Инк. Ингибирование убиквитин-специфической пептидазы 30
EP3710441A1 (en) * 2017-11-17 2020-09-23 Hepagene Therapeutics, Inc. Urea derivatives as inhibitors of ask1
WO2019136025A1 (en) 2018-01-02 2019-07-11 Seal Rock Therapeutics, Inc. Ask1 inhibitor compounds and uses thereof
EP3773577A4 (en) 2018-04-12 2021-12-01 Terns, Inc. TRICYCLIC ASK1 INHIBITORS
WO2019213244A1 (en) 2018-05-02 2019-11-07 Enanta Pharmaceuticals, Inc. Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
WO2019213239A1 (en) 2018-05-02 2019-11-07 Enanta Pharmaceuticals Inc. Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
MX2020012180A (es) 2018-05-17 2021-01-29 Forma Therapeutics Inc Compuestos biciclicos fusionados utiles como inhibidores de la peptidasa 30 especifica de ubiquitina.
TWI710561B (zh) 2018-07-20 2020-11-21 大陸商福建廣生堂藥業股份有限公司 作為ask1抑制劑的晶型及其製備方法和應用
WO2020030107A1 (zh) * 2018-08-10 2020-02-13 江苏豪森药业集团有限公司 一种含有酰胺类衍生物的药物组合物及其制备方法和应用
CN110818683B (zh) * 2018-08-10 2023-04-14 中国科学院上海药物研究所 2-吡啶取代脲结构小分子化合物及其合成和应用
WO2020034988A1 (zh) * 2018-08-14 2020-02-20 江苏豪森药业集团有限公司 凋亡信号调节激酶1抑制剂的盐及其晶型
US10968199B2 (en) 2018-08-22 2021-04-06 Enanta Pharmaceuticals, Inc. Cycloalkyl-containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
JP2022500499A (ja) 2018-09-07 2022-01-04 ピク セラピューティクス， インコーポレイテッド Ｅｉｆ４ｅ阻害剤およびその使用
CN110922407B (zh) * 2018-09-19 2021-11-12 广东东阳光药业有限公司 苯甲酰氨基吡啶衍生物的晶型及其用途
MX2021002981A (es) 2018-10-05 2021-05-14 Forma Therapeutics Inc Pirrolinas fusionadas que actuan como inhibidores de la proteasa 30 especifica de la ubiquitina (usp30).
KR102288434B1 (ko) * 2018-10-18 2021-08-12 에이치케이이노엔 주식회사 신규한 (이소프로필-트리아졸릴)피리디닐 치환된 벤조옥사지논 또는 벤조티아지논 유도체 및 이의 용도
KR102298546B1 (ko) 2018-10-18 2021-09-08 에이치케이이노엔 주식회사 신규한 n-(이소프로필-트리아졸릴)피리디닐)-헤테로아릴-카르복사미드 유도체 및 이의 용도
CN111170995A (zh) * 2018-11-09 2020-05-19 山东轩竹医药科技有限公司 Ask1抑制剂及其应用
WO2020106707A1 (en) 2018-11-19 2020-05-28 Enanta Pharmaceuticals, Inc. Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
US11466033B2 (en) 2019-03-25 2022-10-11 Enanta Pharmaceuticals, Inc. Substituted pyridines as apoptosis signal-regulating kinase 1 inhibitors
CN110577538B (zh) * 2019-07-16 2021-07-23 广州安岩仁医药科技有限公司 苯甲酰氨基吡啶衍生物的盐及其在药物中的应用
CN110577534B (zh) * 2019-07-16 2021-07-23 广州安岩仁医药科技有限公司 苯甲酰氨基吡啶衍生物的盐及其在药物中的应用
CN110577540B (zh) * 2019-07-16 2021-07-23 广州安岩仁医药科技有限公司 苯甲酰氨基吡啶衍生物的盐及其在药物中的应用
CN110577537B (zh) * 2019-07-16 2021-07-23 广州安岩仁医药科技有限公司 苯甲酰氨基吡啶衍生物的盐及其在药物中的应用
CN110577541B (zh) * 2019-07-16 2021-07-23 广州安岩仁医药科技有限公司 苯甲酰氨基吡啶衍生物的盐及其在药物中的应用
CN110577536B (zh) * 2019-07-16 2021-07-23 广州安岩仁医药科技有限公司 苯甲酰氨基吡啶衍生物的盐及其在药物中的应用
CN110577535B (zh) * 2019-07-16 2021-07-23 广州安岩仁医药科技有限公司 苯甲酰氨基吡啶衍生物的盐及其在药物中的应用
CN110577539B (zh) * 2019-07-16 2021-07-23 广州安岩仁医药科技有限公司 苯甲酰氨基吡啶衍生物的盐及其在药物中的应用
CN110577533B (zh) * 2019-07-16 2021-07-23 广州安岩仁医药科技有限公司 苯甲酰氨基吡啶衍生物的盐及其在药物中的应用
WO2021031071A1 (zh) * 2019-08-19 2021-02-25 广东东阳光药业有限公司 酰胺衍生物及其在药物中的应用
CN112409332B (zh) * 2019-08-23 2023-12-08 广东东阳光药业股份有限公司 三氮唑衍生物及其在药物中的应用
CA3161582A1 (en) * 2019-11-13 2021-05-20 Nippon Shinyaku Co., Ltd. Azabenzimidazole compound and medicine
WO2021220185A1 (en) 2020-05-01 2021-11-04 Pfizer Inc. Azalactam compounds as hpk1 inhibitors
WO2021224818A1 (en) * 2020-05-08 2021-11-11 Pfizer Inc. Isoindolone compounds as hpk1 inhibitors
CN113831323A (zh) * 2020-06-24 2021-12-24 武汉人福创新药物研发中心有限公司 芳杂环酰胺类化合物及其用途

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102482257A (zh) * 2009-07-13 2012-05-30 吉利德科学股份有限公司 凋亡信号调节激酶抑制剂
CN104080771A (zh) * 2012-01-27 2014-10-01 吉利德科学公司 细胞凋亡信号调节激酶抑制剂
WO2016025474A1 (en) * 2014-08-13 2016-02-18 Gilead Sciences, Inc. Methods of treating pulmonary hypertension
CN109071538A (zh) * 2017-01-22 2018-12-21 福建广生堂药业股份有限公司 作为ask1抑制剂的吡啶衍生物及其制备方法和应用
CN109071448A (zh) * 2017-01-22 2018-12-21 福建广生堂药业股份有限公司 Ask1抑制剂及其制备方法和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200536830A (en) * 2004-02-06 2005-11-16 Chugai Pharmaceutical Co Ltd 1-(2H)-isoquinolone derivative
ES2358618T3 (es) 2006-07-14 2011-05-12 Chemocentryx, Inc. Triazol piridil bencenosulfonamidas como moduladores del ccr2 o ccr9 para el tratamiento de la arteriosclerosis.
EP2058309A4 (en) * 2006-08-04 2010-12-22 Takeda Pharmaceutical CONDENSED HETEROCYCLIC COMPOUND
SI2588475T1 (sl) 2010-07-02 2015-12-31 Gilead Sciences, Inc. Kinazni inhibitorji za regulacijo apoptoznega signala
UY35212A (es) 2012-12-21 2014-06-30 Gilead Sciences Inc Inhibidores de la quinasa que regula la señal de la apoptosis
CR20160268A (es) 2013-12-20 2016-08-16 Gilead Sciences Inc Inhibidores de la quinasa reguladora de la señal de apoptosis
WO2015187499A1 (en) * 2014-06-03 2015-12-10 Gilead Sciences, Inc. Use of an ask1 inhibitor for the treatment of liver disease, optionally in combination with a loxl2 inhibitor
BR112017013382A2 (pt) 2014-12-23 2018-02-14 Gilead Sciences Inc método para preparar um composto, composto, e, ácido.
MA41252A (fr) * 2014-12-23 2017-10-31 Gilead Sciences Inc Formes solides d'un inhibiteur d'ask 1
WO2018090869A1 (zh) * 2016-11-16 2018-05-24 广东东阳光药业有限公司 酰胺衍生物及其在药物中的应用
WO2018151830A1 (en) * 2017-02-17 2018-08-23 Fronthera U.S. Pharmaceuticals Llc Pyridinyl based apoptosis signal-regulation kinase inhibitors
CN107793400B (zh) * 2017-10-31 2020-01-31 武汉九州钰民医药科技有限公司 吡啶类化合物及其在制备治疗肝脏疾病的药物中的应用

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102482257A (zh) * 2009-07-13 2012-05-30 吉利德科学股份有限公司 凋亡信号调节激酶抑制剂
CN104080771A (zh) * 2012-01-27 2014-10-01 吉利德科学公司 细胞凋亡信号调节激酶抑制剂
WO2016025474A1 (en) * 2014-08-13 2016-02-18 Gilead Sciences, Inc. Methods of treating pulmonary hypertension
CN109071538A (zh) * 2017-01-22 2018-12-21 福建广生堂药业股份有限公司 作为ask1抑制剂的吡啶衍生物及其制备方法和应用
CN109071448A (zh) * 2017-01-22 2018-12-21 福建广生堂药业股份有限公司 Ask1抑制剂及其制备方法和应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JUNGHUN LEE等: "Discovery and initial SAR of pyrimidin-4-yl-1H-imidazole derivatives with antiproliferative activity against melanoma cell lines", 《BIOORGANIC & MEDICINAL CHEMISTRY LETTERS》 *
MARION LANIER等: "Structure-Based Design of ASK1 Inhibitors as Potential Agents for Heart Failure", 《ACS MED. CHEM. LETT.》 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110770233A (zh) * 2017-06-19 2020-02-07 广东东阳光药业有限公司 稠合双环类化合物及其在药物中的应用
CN110770233B (zh) * 2017-06-19 2022-07-26 广东东阳光药业有限公司 稠合双环类化合物及其在药物中的应用
CN111518080A (zh) * 2017-10-12 2020-08-11 深圳市塔吉瑞生物医药有限公司 一种1,2,4-三氮唑类化合物
CN109956928A (zh) * 2017-12-14 2019-07-02 四川科伦博泰生物医药股份有限公司 吡啶类化合物、其制备方法及用途
CN110294746A (zh) * 2018-03-21 2019-10-01 山东轩竹医药科技有限公司 一种新的ask1抑制剂及其应用
CN110294746B (zh) * 2018-03-21 2023-01-31 山东轩竹医药科技有限公司 一种新的ask1抑制剂及其应用

Also Published As

Publication number Publication date
WO2018157856A1 (zh) 2018-09-07
CN115504986B (zh) 2024-05-14
CN111094250B (zh) 2022-11-04
EP3590931A4 (en) 2020-11-18
WO2018157857A1 (zh) 2018-09-07
JP7211959B2 (ja) 2023-01-24
CN109983007A (zh) 2019-07-05
JP2020509041A (ja) 2020-03-26
TW201833108A (zh) 2018-09-16
EP3590931A1 (en) 2020-01-08
CN115504986A (zh) 2022-12-23
CN109983007B (zh) 2021-11-05
US20210032249A1 (en) 2021-02-04
US11136324B2 (en) 2021-10-05
KR20190126322A (ko) 2019-11-11

Similar Documents

Publication Publication Date Title
CN111094250B (zh) 凋亡信号调节激酶抑制剂及其制备方法和应用
EP3466929B1 (en) Heterocyclic compounds useful as pdk1 inhibitors
CA2890981C (en) Amide-substituted heterocyclic compounds useful as modulators of il-12, il-23 and/or ifn.alpha. responses
CN111107848B (zh) 一种含有酰胺类衍生物的药物组合物及其制备方法和应用
US20110183975A1 (en) Novel 6-azaindole aminopyrimidine derivatives having nik inhibitory activity
CN110582491A (zh) Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途
WO2023098439A1 (zh) 一种吡唑衍生物，其制备方法和在药学上的应用
JP2010528021A (ja) キナーゼのインヒビターとして有用なチアゾールおよびピラゾール
WO2019062733A1 (zh) Pde9 抑制剂及其用途
EP2560655B1 (en) Substituted pyrimidines
EP3892621B1 (en) Haloallylamine compounds and application thereof
CN107312009B (zh) 喹啉类化合物、其制备方法、中间体、药物组合物和应用
TW201917129A (zh) 含吡唑基的三并環類衍生物、其製備方法和應用
CN114437116A (zh) 杂环化合物及其制备方法、药物组合物和应用
WO2021083383A1 (zh) 一类含氮稠环类sting调节剂类化合物、制备方法和用途
US20110152304A1 (en) Spiroazaindoles
CN111170995A (zh) Ask1抑制剂及其应用
CN110294742B (zh) 并环类ask1抑制剂及其应用
CN113429440A (zh) 一种螺环化合物的前药、其制备方法及其在医药上的应用
AU2023268460A1 (en) Inhibitors of human respiratory syncytial virus and metapneumovirus
CN117683042A (zh) 稠合四环类化合物、其制备方法及其在医药上的应用
WO2024140319A1 (zh) 一种嘧啶类化合物及其制备方法和医药用途
WO2023236960A1 (zh) 一种具有rsk抑制作用的羧酰胺衍生物、包含其的药物组合物及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant